Skip to content


Januvia, Ristaben, Tesavel, Xelevia (sitagliptin) is a small molecule pharmaceutical. Sitagliptin was first approved as Januvia on 2006-10-16. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. In addition, it is known to target dipeptidyl peptidase 4. Januvia's patents are valid until 2026-11-24 (FDA).
Trade Name Januvia, Ristaben, Tesavel, Xelevia
Common Name Sitagliptin
Indication type 2 diabetes mellitus
Drug Class Dipeptidyl aminopeptidase-IV inhibitors
Get full access now